Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
|
|
Prometheus Biosciences, Inc. (RXDX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/09/2023 |
8-K
| Quarterly results|
Docs:
|
"Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate Progress - Entered into agreement to be acquired by Merck; transaction expected to close in 3Q 2023 - SAN DIEGO, May 9, 2023 -- Prometheus Biosciences, Inc. , a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutics for the treatment of immune-mediated diseases, today reported financial results for the quarter ended March 31, 2023. Prometheus to be Acquired by Merck On April 15, 2023, Merck and Prometheus Biosciences entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximatel..." |
|
| 11/09/2022 |
8-K
| Quarterly results |
| 08/11/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 03/09/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
|
|